Promising New Approach to Treat BRCA-Associated Breast Cancers Found by Cambridge Researchers

Promising new approach to treat BRCA-associated breast cancers found by Cambridge researchers

There was a 100% survival rate among patients in trial during three-year period.

Breakthrough in treating aggressive breast cancer improves patient survival

A new treatment approach for aggressive breast cancers significantly improves survival rates for patients In a new trial by the University of Cambridge, researchers found that aggressive breast cancers were treated with chemotherapy followed by a targeted cancer drug before surgery; 100% of patients survived the critical three-year period post-surgery. This discovery could become the most effective treatment to date for patients with early-stage…

A new treatment approach significantly improves the survival rates of patients with aggressive hereditary breast cancers, according to researchers at the University of Cambridge, United Kingdom. The discovery, published in ‘Nature Communications’, could become the most effective treatment to date for patients with early breast cancer with inherited mutations in the BRCA1 and BRCA2 genes. In a trial that treated cancers with chemotherapy followed…

Targeted Pre-Surgery Drug Boosts Survival in Inherited Breast Cancer

A new treatment strategy could redefine the standard of care for patients with early-stage BRCA1/2-mutated breast cancer. In the PARTNER trial led by the University of Cambridge and Addenbrooke’s Hospital, patients receiving a neoadjuvant (pre-surgery) combination of carboplatin-based chemotherapy and olaparib, a targeted PARP inhibitor, achieved 100% overall survival at 36 months, compared to 88% in the standard treatment group. The findings, p…

A new approach has been tested for the treatment of hereditary cancers linked to mutations in the BRCA1 and BRCA2 genes. While the results are promising, they need to be confirmed by a larger study.